FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318302179> ?p ?o ?g. }

• W4318302179 endingPage "e177" @default.
• W4318302179 startingPage "e168" @default.
• W4318302179 abstract "Background Clinical trial data are scarce for the use of prophylaxis in people with non-severe haemophilia A. The HAVEN 6 study aims to assess safety and efficacy of emicizumab prophylaxis in people with non-severe haemophilia A without factor VIII (FVIII) inhibitors. Methods HAVEN 6 is a multicentre, open-label, single-arm, phase 3 study taking place in 22 specialty clinics and hospitals in Europe, North America, and South Africa. Eligible participants were people of all ages weighing at least 3 kg with a diagnosis of moderate (FVIII activity ≥1%–≤5%) or mild (FVIII >5%–<40%) haemophilia A without FVIII inhibitors requiring prophylaxis as assessed by the treating physician. Participants received subcutaneous emicizumab 3 mg/kg of bodyweight once weekly for 4 weeks, followed by the participant's choice of maintenance dose: 1·5 mg/kg once weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks. Safety was the primary objective of the study. Safety endpoints included adverse events, serious adverse events, and adverse events of special interest including thromboembolic events and thrombotic microangiopathies. The primary efficacy endpoint was the annualised bleed rate for treated bleeds. Analyses were done for participants who received at least one dose of emicizumab. This study is registered with ClinicalTrials.gov, number NCT04158648, and is active but not recruiting. Findings Between Feb 10, 2020, and Aug 31, 2021, we assigned 73 people to treatment. 72 participants received at least one dose of emicizumab (51 moderate [71%]; 21 mild [29%]; 69 male [96%]; three female [4%]; and 61 White [85%]). Median age was 23·5 years (IQR 12·0–36·0); median follow-up was 55·6 weeks (IQR 52·3–61·6) weeks. At baseline, 24 participants (33%) had target joints and 37 (51%) were receiving FVIII prophylaxis. 60 participants (83%) had at least one adverse event; the most common adverse events were headache (in 12 participants [17%]), injection-site reaction (12 [17%]), and arthralgia (11 [15%]). 15 (21%) had at least one emicizumab-related adverse event; no adverse events led to treatment withdrawal, modification, or interruption. Eight participants (11%) reported ten serious adverse events in total, none emicizumab-related. There were no deaths or thrombotic microangiopathies. One participant had grade 1 thrombosed haemorrhoids (classified as a thromboembolic event), unrelated to emicizumab. The annualised bleed rate was 0·9 (95% CI 0·55–1·52) for treated bleeds. 48 participants (67%) had no treated bleeds. All-bleed annualised bleed rates were 10·1 (95% CI 6·93–14·76) from 24 weeks pre-study and 2·3 (1·67–3·12) on-study after a median follow-up of 55·6 weeks. Interpretation These data show efficacy and a favourable safety profile of emicizumab in people with non-severe haemophilia A without FVIII inhibitors who warrant prophylaxis, confirming emicizumab as a valuable treatment option in this population. Funding F Hoffmann-La Roche." @default.
• W4318302179 created "2023-01-28" @default.
• W4318302179 creator A5001400341 @default.
• W4318302179 creator A5008435049 @default.
• W4318302179 creator A5012815766 @default.
• W4318302179 creator A5017113740 @default.
• W4318302179 creator A5020001100 @default.
• W4318302179 creator A5020816857 @default.
• W4318302179 creator A5026562020 @default.
• W4318302179 creator A5038597185 @default.
• W4318302179 creator A5050723834 @default.
• W4318302179 creator A5064079929 @default.
• W4318302179 creator A5064355731 @default.
• W4318302179 creator A5064882373 @default.
• W4318302179 creator A5066370748 @default.
• W4318302179 creator A5072973093 @default.
• W4318302179 creator A5078411281 @default.
• W4318302179 creator A5079861916 @default.
• W4318302179 creator A5086231738 @default.
• W4318302179 creator A5086865217 @default.
• W4318302179 date "2023-03-01" @default.
• W4318302179 modified "2023-10-16" @default.
• W4318302179 title "Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study" @default.
• W4318302179 cites W1990166011 @default.
• W4318302179 cites W2017096523 @default.
• W4318302179 cites W2020123164 @default.
• W4318302179 cites W2064449670 @default.
• W4318302179 cites W2089165963 @default.
• W4318302179 cites W2279300874 @default.
• W4318302179 cites W2607655971 @default.
• W4318302179 cites W2726248338 @default.
• W4318302179 cites W2734287351 @default.
• W4318302179 cites W2885455946 @default.
• W4318302179 cites W2888504165 @default.
• W4318302179 cites W2888898681 @default.
• W4318302179 cites W2936143155 @default.
• W4318302179 cites W2946798660 @default.
• W4318302179 cites W2961043876 @default.
• W4318302179 cites W2980900975 @default.
• W4318302179 cites W3034093413 @default.
• W4318302179 cites W3037252784 @default.
• W4318302179 cites W3047046471 @default.
• W4318302179 cites W3115183047 @default.
• W4318302179 cites W3197167619 @default.
• W4318302179 cites W3204695865 @default.
• W4318302179 cites W3213505659 @default.
• W4318302179 cites W4206255949 @default.
• W4318302179 cites W4212987541 @default.
• W4318302179 cites W4235469187 @default.
• W4318302179 cites W4308962120 @default.
• W4318302179 doi "https://doi.org/10.1016/s2352-3026(22)00377-5" @default.
• W4318302179 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36716761" @default.
• W4318302179 hasPublicationYear "2023" @default.
• W4318302179 type Work @default.
• W4318302179 citedByCount "11" @default.
• W4318302179 countsByYear W43183021792023 @default.
• W4318302179 crossrefType "journal-article" @default.
• W4318302179 hasAuthorship W4318302179A5001400341 @default.
• W4318302179 hasAuthorship W4318302179A5008435049 @default.
• W4318302179 hasAuthorship W4318302179A5012815766 @default.
• W4318302179 hasAuthorship W4318302179A5017113740 @default.
• W4318302179 hasAuthorship W4318302179A5020001100 @default.
• W4318302179 hasAuthorship W4318302179A5020816857 @default.
• W4318302179 hasAuthorship W4318302179A5026562020 @default.
• W4318302179 hasAuthorship W4318302179A5038597185 @default.
• W4318302179 hasAuthorship W4318302179A5050723834 @default.
• W4318302179 hasAuthorship W4318302179A5064079929 @default.
• W4318302179 hasAuthorship W4318302179A5064355731 @default.
• W4318302179 hasAuthorship W4318302179A5064882373 @default.
• W4318302179 hasAuthorship W4318302179A5066370748 @default.
• W4318302179 hasAuthorship W4318302179A5072973093 @default.
• W4318302179 hasAuthorship W4318302179A5078411281 @default.
• W4318302179 hasAuthorship W4318302179A5079861916 @default.
• W4318302179 hasAuthorship W4318302179A5086231738 @default.
• W4318302179 hasAuthorship W4318302179A5086865217 @default.
• W4318302179 hasBestOaLocation W43183021791 @default.
• W4318302179 hasConcept C126322002 @default.
• W4318302179 hasConcept C141071460 @default.
• W4318302179 hasConcept C187212893 @default.
• W4318302179 hasConcept C197934379 @default.
• W4318302179 hasConcept C203092338 @default.
• W4318302179 hasConcept C2776259030 @default.
• W4318302179 hasConcept C2777232031 @default.
• W4318302179 hasConcept C2778385053 @default.
• W4318302179 hasConcept C535046627 @default.
• W4318302179 hasConcept C71924100 @default.
• W4318302179 hasConceptScore W4318302179C126322002 @default.
• W4318302179 hasConceptScore W4318302179C141071460 @default.
• W4318302179 hasConceptScore W4318302179C187212893 @default.
• W4318302179 hasConceptScore W4318302179C197934379 @default.
• W4318302179 hasConceptScore W4318302179C203092338 @default.
• W4318302179 hasConceptScore W4318302179C2776259030 @default.
• W4318302179 hasConceptScore W4318302179C2777232031 @default.
• W4318302179 hasConceptScore W4318302179C2778385053 @default.
• W4318302179 hasConceptScore W4318302179C535046627 @default.
• W4318302179 hasConceptScore W4318302179C71924100 @default.
• W4318302179 hasFunder F4320309432 @default.
• W4318302179 hasFunder F4320323878 @default.

• next